Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances

Larry A. Bauer; Douglas J. Black; Jennifer S. Lill; Julie Garrison; Vidmantas A. Raisys; Thomas M. Hooton

doi:10.1128/AAC.49.4.1649-1651.2005

Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances

Larry A. Bauer, Douglas J. Black, Jennifer S. Lill, Julie Garrison, Vidmantas A. Raisys, Thomas M. Hooton

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Ten healthy adults participated in a randomized, crossover drug interaction study testing procainamide only, procainamide plus levofloxacin, and procainamide plus ciprofloxacin. During levofloxacin therapy, most procainamide and N-acetylprocainamide (NAPA) pharmacokinetic parameters, including decreased renal clearances and renal clearance/creatinine clearance ratios, changed (P < 0.05). During ciprofloxacin treatment, only procainamide and NAPA renal clearances decreased significantly.

Original language	English (US)
Pages (from-to)	1649-1651
Number of pages	3
Journal	Antimicrobial agents and chemotherapy
Volume	49
Issue number	4
DOIs	https://doi.org/10.1128/AAC.49.4.1649-1651.2005
State	Published - Apr 2005
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.49.4.1649-1651.2005

Fingerprint Dive into the research topics of 'Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances'. Together they form a unique fingerprint.

Cite this

@article{43b5e40857804154aa17e14902e15292,

title = "Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances",

abstract = "Ten healthy adults participated in a randomized, crossover drug interaction study testing procainamide only, procainamide plus levofloxacin, and procainamide plus ciprofloxacin. During levofloxacin therapy, most procainamide and N-acetylprocainamide (NAPA) pharmacokinetic parameters, including decreased renal clearances and renal clearance/creatinine clearance ratios, changed (P < 0.05). During ciprofloxacin treatment, only procainamide and NAPA renal clearances decreased significantly.",

author = "Bauer, {Larry A.} and Black, {Douglas J.} and Lill, {Jennifer S.} and Julie Garrison and Raisys, {Vidmantas A.} and Hooton, {Thomas M.}",

year = "2005",

month = apr,

doi = "10.1128/AAC.49.4.1649-1651.2005",

language = "English (US)",

volume = "49",

pages = "1649--1651",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "4",

}

TY - JOUR

T1 - Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances

AU - Bauer, Larry A.

AU - Black, Douglas J.

AU - Lill, Jennifer S.

AU - Garrison, Julie

AU - Raisys, Vidmantas A.

AU - Hooton, Thomas M.

PY - 2005/4

Y1 - 2005/4

N2 - Ten healthy adults participated in a randomized, crossover drug interaction study testing procainamide only, procainamide plus levofloxacin, and procainamide plus ciprofloxacin. During levofloxacin therapy, most procainamide and N-acetylprocainamide (NAPA) pharmacokinetic parameters, including decreased renal clearances and renal clearance/creatinine clearance ratios, changed (P < 0.05). During ciprofloxacin treatment, only procainamide and NAPA renal clearances decreased significantly.

AB - Ten healthy adults participated in a randomized, crossover drug interaction study testing procainamide only, procainamide plus levofloxacin, and procainamide plus ciprofloxacin. During levofloxacin therapy, most procainamide and N-acetylprocainamide (NAPA) pharmacokinetic parameters, including decreased renal clearances and renal clearance/creatinine clearance ratios, changed (P < 0.05). During ciprofloxacin treatment, only procainamide and NAPA renal clearances decreased significantly.

UR - http://www.scopus.com/inward/record.url?scp=16244408295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16244408295&partnerID=8YFLogxK

U2 - 10.1128/AAC.49.4.1649-1651.2005

DO - 10.1128/AAC.49.4.1649-1651.2005

M3 - Article

C2 - 15793163

AN - SCOPUS:16244408295

VL - 49

SP - 1649

EP - 1651

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -